State-of-the-Art Review: Cardiovascular Disease in Patients With Chronic Myeloid Leukemia
Dasatinib has been associated with the development of pulmonary arterial hypertension, while nilotinib and ponatinib have been linked to various vascular complications.
This comprehensive review summarizes cardiovascular (CV) risk factors and complications in patients with chronic myeloid leukemia (CML) treated with BCR::ABL1 tyrosine kinase inhibitors (TKIs). It highlights the prevalence of baseline CV disease, the spectrum of TKI‑induced CV toxicities—particularly pulmonary arterial hypertension with dasatinib and vascular events with nilotinib and ponatinib—and the importance of baseline CV risk assessment to guide TKI selection and management. The review emphasizes the need for systematic CV monitoring in clinical trials and clinical practice to mitigate morbidity and mortality.
Patients with CML are now living longer due to targeted TKI therapy, but the chronic use of these agents increases the risk of potentially life‑threatening cardiovascular events. Early identification and proactive management of CV risk factors are essential to maintain quality of life and treatment adherence.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Treatment of chronic myeloid leukemia chronic phase patients in third-line setting and beyond: recommendations from a Belgian expert panel in 2025
- Chronic myeloid leukemia: Current guidelines for diagnosis and management
- Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment‑free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co‑primary endpoint
- Information about Project 4: Chronic myeloid leukemia (CML)
- Prevalence and characterization of germline RAS pathway variants in children with chronic myeloid leukemia